Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of rheumatoid arthritis with a DR4/1 peptide
Autore:
St Clair, EW; Cohen, SB; Lee, ML; Fleischmann, RM; Lee, SH; Moreland, LW; Olsen, NJ; Pratt, PW; Yocum, DE; Heck, L; Winkelhake, J; Holcenberg, JS; Shulman, MJ;
Indirizzi:
Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 iv, Med Ctr, Dept Med, Durham, NC 27710 USA Univ Alabama, Dept Med, Birmingham, AL 35294 USA Univ Alabama Birmingham AL USA 35294 , Dept Med, Birmingham, AL 35294 USA Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA Univ Arizona Tucson AZ USAUniv Arizona, Hlth Sci Ctr, Tucson, AZ USA Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA Univ CalifLos Angeles Los Angeles CA USA 90024 Los Angeles, CA 90024 USA Hosp Joint Dis, New York, NY USA Hosp Joint Dis New York NY USAHosp Joint Dis, New York, NY USA Rheumatol Associates, Dallas, TX USA Rheumatol Associates Dallas TX USARheumatol Associates, Dallas, TX USA Dothan Specialty Clin, Dothan, AL USA Dothan Specialty Clin Dothan AL USA othan Specialty Clin, Dothan, AL USA Corixa Corp, Redwood City, CA USA Corixa Corp Redwood City CA USACorixa Corp, Redwood City, CA USA
Titolo Testata:
JOURNAL OF RHEUMATOLOGY
fascicolo: 8, volume: 27, anno: 2000,
pagine: 1855 - 1863
SICI:
0315-162X(200008)27:8<1855:TORAWA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
T-CELL-RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; 3RD HYPERVARIABLE REGION; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HLA-DR ALLELES; II BETA-CHAIN; ACETYLCHOLINE-RECEPTOR; BINDING-SPECIFICITY; IMMUNE-RESPONSES; MICE;
Keywords:
rheumatoid arthritis; HLA-DR; shared epitope; vaccine; antirheumatic therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: St Clair, EW Duke Univ, Med Ctr, Dept Med, Box 3874, Durham, NC 27710 USA Duke Univ Box 3874 Durham NC USA 27710 , Durham, NC 27710 USA
Citazione:
E.W. St Clair et al., "Treatment of rheumatoid arthritis with a DR4/1 peptide", J RHEUMATOL, 27(8), 2000, pp. 1855-1863

Abstract

Objective, To determine the safety and potential clinical efficacy of primary and booster injections of a DR4/1 peptide in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. Methods. Subjects with active RA were enrolled in a randomized, placebo controlled, double blind, dose-escalating clinical trial of synthetic DR4/1 peptide containing the shared epitope. The primary injection of the DR4/1 peptide in alum adjuvant was administered at one of 3 doses, 1.3, 4.0, and 13mg, followed by up to 3 or 4 booster injections every 6 or 8 weeks at the same dose. The primacy outcomes were the occurrence of adverse effects and changes in measures of immune function. Clinical efficacy was assessed using the American College of Rheumatology 20% criteria for clinical improvement. Results. Fifty-three patients were entered into the trial, including 44 who completed the study. In the absence of any observations of a dose response to the DR4/1 peptide injections, the 3 dosage groups were combined for subsequent analysis into 3 groups: patients receiving DR4/1 peptide injections every 6 weeks, patients receiving DR4/1 peptide injections every 8 weeks,and a placebo group. At all doses and each dosing interval the primary andbooster injections of synthetic DR4/1 peptide were well tolerated and did not produce any significant changes in lymphocyte counts or evidence of generalized immunosuppression. Analysis of clinical efficacy showed that the 6week group had trends toward improvement in disease measures. Conclusion. Primary and booster injections of the DR4/1 peptide containingthe shared epitope were safe and did not broadly suppress immune function.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 20:13:46